The study evaluated the referral pattern and sensitivity of using OVA1 against multiple triage methods to direct adnexal masses to gynecologic oncologists for possible malignancy. 770 intended use patients were enrolled by non-gynecologic oncologists from two related, multi-institutional, prospective trials and analyzed retrospectively. 
OVA1 was associated with a gynecologic oncologist referral rate (56%) comparable to actual clinical practice (60%) and had higher sensitivity for malignancy than clinical assessment, CA125, and modified-ACOG guidelines.
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Objective
The study compared OVA1 head-to-head or in combination with ultrasound (US) or CT scan to predict the likelihood of ovarian malignancy before surgery. 1024 evaluable patients from previously performed, prospective national trials, that included 44 clinical sites from the years 2007 through 2012, were retrospectively analyzed for the following end points:
Sensitivity: The percent of patients with a malignant mass who had a positive test result

Specificity: The percent of patients with a benign mass who had a negative test result
Key Results
• US alone missed 23% (21/91) of ovarian cancers compared to 11% (10/91) by OVA1 as a standalone test; results were similar in comparing CT scan alone and OVA1.
• Adding OVA1 to US reduced ovarian cancer missed to just 2% (2/91)
• Specificity of OVA1 alone was comparable to US (51% vs 55%) in 630 benign patients
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